Novacyt (NCYT)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 39.05 |
|---|---|
| 52-week range | 26.60 – 86.00 |
| Return, 1 month / 3 months | −7.9% / +2.8% |
| Return, 1 year / 3 years | −7.5% / −16.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 43 |
| Volatility (1 year) | 92.7% |
| Worst drawdown (1 year) | -57.4% |
| Average daily value traded | 3.79M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novacyt is a diagnostics company that develops and supplies molecular testing products, including PCR-based tests, reagents and laboratory instruments. Its products are used by clinical laboratories, hospitals and healthcare providers to detect infectious diseases and other conditions. The company also offers contract manufacturing and diagnostic services. Novacyt is based in France, with operations in the United Kingdom and other markets, and serves customers across Europe and internationally.
Novacyt trades under the code NCYT on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novacyt (NCYT) trades on the London Exchange in UK. It last closed at GBX 39.05 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,298 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.5% and over the last three months it rose 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.4% | ||
| From 52-week high | -49.5% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.8% | ||
| 6-month return | 22.8% | ||
| 12-month return, skipping the last month | 0.5% | ||
| Stability (higher is calmer) | 11 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 92.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -57.4% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.79M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.4% |
|---|---|
| 1 month | −7.9% |
| 3 months | +2.8% |
| 6 months | +22.8% |
| 1 year | −7.5% |
| 3 years | −16.2% |
| 5 years | −86.3% |
Signals
| 50-day / 200-day average | 42.25 / 38.13 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.18 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.